争议药物avacopan的安全性研究结果出炉
Safety of Controversial Vasculitis Drug Bolstered in Dedicated Trial
一项专门评估avacopan安全性的前瞻性研究结果显示,尽管肝损伤风险较高,但并不常见且不严重。这些发现可能有助于avacopan在美国市场继续存在。
新安全研究显示,avacopan 的肝损伤风险可控,可能帮助其在美国市场继续存在。
— Findings might help avacopan's fight to stay in the U.S. market
by John Gever, Contributing Writer, MedPage Today
November 9, 2026 • 4 min read
ORLANDO -- Interim results from a prospective trial designed to evaluate safety of avacopan (Tavneos), the embattled drug for antineutrophil cytoplasmic antibody-associated vasculitis (AAV), indicated that the product could still avoid total extinction.
Patients receiving avacopan in the trial, dubbed AvacoStar, experienced a fourfold higher rate of liver abnormalities compared with those treated instead with rituximab (Rituxan) or cyclophosphamide, as Bernhard Hellmich, MD, of the University of Tübingen in Germany, reported at the American College of Rheumatology's annual meeting.
However, these liver abnormalities were neither common nor severe, and other significant adverse effects were no more common with avacopan than with the standard-of-care alternatives.
The findings should be a welcome boost for avacopan, for which 2026 was a very bad year. When it was approved for AAV in 2021, this drug that targets the complement pathway was seen as a valuable addition to treatment options. AAV was treated historically with corticosteroids, despite the serious adverse effects that come with chronic use. Rituximab and cyclophosphamide then joined the armamentarium, but they carry safety risks as well.
Avacopan ran into trouble earlier this year when it was revealed that its original developer, ChemoCentryx, had results from the drug's pivotal registration trial "readjudicated" after unblinding, which shifted some patients from nonresponders to responders. The original findings indicated that the primary endpoint was missed; following the changes, it was achieved.
The appearance of data manipulation set off a firestorm. Liver abnormalities were a known issue with avacopan, but a label warning was considered enough to mitigate the risks. But when the readjudication was discovered, the FDA asked Amgen, which assumed control of avacopan in the U.S. after buying ChemoCentryx in 2022, to take the drug off the market voluntarily. The liver problems gained even more prominence in March when the FDA linked avacopan to eight deaths and 76 worldwide cases of drug-induced liver injury, including 54 hospitalizations.
Across the Atlantic, meanwhile, the controversy over data integrity in the pivotal trial prompted British and European regulators to order avacopan's withdrawal. Its marketing authorization was revoked in August in the European Union, while its withdrawal in the U.K. will be completed by this coming March.
Thus far, Amgen has rejected the FDA's withdrawal request, and the agency has not made it mandatory. Findings from the new safety study, along with an Italian study published last month that confirmed avacopan's efficacy in AAV, might be enough to keep the drug available in the U.S., at least for the time being.
AvacoStar was started in 2023 by Vifor Fresenius Medical Care Renal Pharma -- a joint venture between Fresenius Medical Care and what is now CSL Vifor, which had licensed avacopan from ChemoCentryx in Europe and felt a dedicated safety study was needed. The study enrolled 504 patients with highly active AAV in Britain and Germany who would be given either avacopan or one of the more conventional alternatives at clinicians' discretion, with 254 receiving avacopan and 250 an alternative regimen.
Outcomes were four types of "medical events of special interest," which included liver injury, cardiovascular events, serious infections, and malignancies -- altogether with 101 events in 72 patients (28.3%, 0.30 per patient-year). These were identified from participants' subsequent medical records. The study is still ongoing, with final completion scheduled in 2030. Hellmich's report involved data extracted as of September 2025, at which point more than 95% of patients were still on their original therapy, with mean duration of 16.2 months for avacopan and 12.7 months for the alternatives.
Mean patient age was about 64, and half of them were men. Specific AAV subtypes were equally split between granulomatosis with polyangiitis and microscopic polyangiitis. Almost three-quarters of patients were newly diagnosed. Half of them had serious renal impairment, including some 20% with estimated glomerular filtration rate less than 15 mL/min/1.73 m2.
Liver injury was the only medical event of special interest that was significantly more common with avacopan (IRR 4.03, 95% CI 1.55-10.48), and the absolute rate was reassuringly low, at 0.07 per patient-year (95% CI 0.05-0.10). Serious infections were the most common, at 0.14 per patient-year in the avacopan group, compared with 0.18 per patient-year with rituximab or cyclophosphamide. Cardiac events occurred at 0.09 per patient-year in both groups, and malignancies were also seen at equal rates, 0.02 per patient-year.
Most liver events with avacopan happened in the first 6 months of treatment, Hellmich said. Of the 22 such events overall, 10 were considered by treating clinicians to be probably or definitely unrelated to the drug. Among the 12 cases considered possibly, probably, or certainly due to avacopan, three continued with their regular dosing and five stopped it temporarily.
Hellmich also emphasized that 20 of the 22 cases had resolved before the interim data cut. One of the other two was reported to have been resolved later, while the last had not but, Hellmich said, was thought to be "clinically irrelevant."
With regard to study limitations, he cautioned that, because site investigators chose treatments based on their own judgments, "residual bias" is a possibility. As well, final results with additional years of treatment might reveal risks not yet apparent.
来源:MedPage Today · medpagetoday.com